{"title": "PREVNAR\u00ae 13 Warnings and Precautions (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein)", "author": null, "url": "https://www.pfizermedicalinformation.com/en-us/prevnar-13/warnings", "hostname": "pfizermedicalinformation.com", "description": "5 WARNINGS AND PRECAUTIONS 5.1 Management of Allergic Reactions Epinephrine and other appropriate agents used to manage immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur following administration of", "sitename": "pfizermedicalinformation.com", "date": "2023-01-01", "cleaned_text": "5 WARNINGS AND PRECAUTIONS 5.1 Management of Allergic Reactions Epinephrine and other appropriate agents used to manage immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur following administration of Prevnar 13. 5.2 Altered Immunocompetence Individuals with altered immunocompetence, including those at higher risk for invasive pneumococcal disease (e.g., individuals with congenital or acquired splenic dysfunction, HIV infection, malignancy, hematopoietic stem cell transplant, nephrotic syndrome), may have reduced antibody responses to immunization with Prevnar 13 [see [Use in Specific Populations (8.6)](#S8.6)]. 5.3 Apnea in Premature Infants Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including Prevnar 13, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination. "}